Novo Nordisk's net profit increased by 12% in the first nine months of 2021
Financial report for the period 1 January 2021 to 30 September 2021
3 November 2021
Novo Nordisk's net profit increased by 12% in the first nine months of 2021
- Operating profit increased by 5% in Danish kroner and by 12% at constant exchange rates (CER).
- Sales increased by 8% in Danish kroner and by 13% at CER to DKK 102.5 billion. Sales in International Operations increased by 10% in Danish kroner (13% at CER), and sales in North America Operations increased by 6% in Danish kroner (13% at CER).
- Sales within Diabetes and Obesity care increased by 10% in Danish kroner to DKK 88.0 billion (15% at CER), driven by GLP-1 growth of 24% in Danish kroner (30% at CER) reflecting the uptake of Ozempic® and Rybelsus®. Obesity care grew by 41% in Danish kroner (49% at CER) and Biopharm sales remained unchanged in Danish kroner (increased by 4% at CER).
- Sales in the third quarter increased by 15% in Danish kroner (15% at CER) compared to the third quarter of 2020. Sales growth was driven by diabetes GLP-1 growth of 30% in Danish kroner (31% at CER) and Obesity care growth of 79% in Danish kroner (82% at CER) reflecting market expansion and the launch of Wegovy™ in the US.
- Within R&D, Novo Nordisk initiated phase 3 development with both oral semaglutide 50 mg for the treatment of obesity and with ziltivekimab in cardiovascular disease during the third quarter.
- On 29 October, the 2021 outlook was raised with sales growth and operating profit growth now both expected to be 12-15% at CER. Sales and operating profit growth reported in Danish kroner is now expected to be 3 and 4 percentage points lower than at CER, respectively. The ongoing share buyback programme is expanded by DKK 2.0 billion to DKK 20 billion.
PROFIT AND LOSS | 9M 2021 | 9M 2020 | Growth as reported | Growth at CER* |
DKK million | ||||
Net sales | 102,467 | 94,808 | 8% | 13% |
Operating profit | 45,010 | 42,948 | 5% | 12% |
Net profit | 36,865 | 32,820 | 12% | N/A |
Diluted earnings per share (in DKK) | 15.98 | 14.00 | 14% | N/A |
* CER: Constant exchange rates (average 2020).
Lars Fruergaard Jørgensen, president and CEO: "We are very pleased with the sales growth in the first nine months of 2021 which has enabled us to raise our outlook for the full year. The growth is driven by all geographical areas and by all therapy areas, in particular by accelerated growth of our portfolio of GLP-1 treatments for diabetes and obesity. In the US, the initial demand for Wegovy™ has significantly exceeded our expectations, underscoring the high unmet need for people living with obesity. With the initiation of two phase 3 programmes in the third quarter, we continue to expand our late-stage clinical pipeline."
On 3 November 2021 at 13.00 CET, corresponding to 08.00 AM EDT, an earnings call will be held. Investors will be able to listen in via a link on novonordisk.com, which can be found under ‘Investors’.
About Novo Nordisk
Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 47,000 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn, YouTube.
Financial calendar | |
2 February 2022 | Financial statement for 2021 |
3 March 2022 | Capital Markets Day in Copenhagen, Denmark |
24 March 2022 | Annual General Meeting |
4 May 2022 | Financial statement for the first three months of 2022 |
4 August 2022 | Financial statement for the first six months of 2022 |
2 November 2022 | Financial statement for the first nine months of 2022 |
Contacts for further information | ||
Media: | ||
Mette Kruse Danielsen | +45 3079 3883 | mkd@novonordisk.com |
Michael Bachner (US) | +1 609 664 7308 | mzyb@novonordisk.com |
Investors: | ||
Daniel Muusmann Bohsen | +45 3075 2175 | dabo@novonordisk.com |
Ann Søndermølle Rendbæk | +45 3075 2253 | arnd@novonordisk.com |
David Heiberg Landsted | +45 3077 6915 | dhel@novonordisk.com |
Mark Joseph Root (US) | +1 848 213 3219 | mjhr@novonordisk.com |
Further information about Novo Nordisk is available on novonordisk.com.
Company announcement No 66 / 2021
Attachment
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Nokia Corporation - Managers' transactions (Uitto)24.4.2024 11:00:00 CEST | Press release
Nokia Corporation Managers’ transactions 24 April 2024 at 12:00 EEST Nokia Corporation - Managers' transactions (Uitto) Transaction notification under Article 19 of EU Market Abuse Regulation. ____________________________________________ Person subject to the notification requirement Name: Uitto, Tommi Position: Other senior manager Issuer: Nokia Corporation LEI: 549300A0JPRWG1KI7U06 Notification type: INITIAL NOTIFICATION Reference number: 59445/5/4 ____________________________________________ Transaction date: 2024-04-23 Venue: NASDAQ HELSINKI LTD (XHEL) Instrument type: SHARE ISIN: FI0009000681 Nature of the transaction: ACQUISITION Transaction details (1): Volume: 173 Unit price: 3.45110 EUR Aggregated transactions (1): Volume: 173 Volume weighted average price: 3.45110 EUR About Nokia At Nokia, we create technology that helps the world act together. As a B2B technology innovation leader, we are pioneering networks that sense, think and act by leveraging our work across mobile, fix
Nokia Corporation - Managers' transactions (Martikainen)24.4.2024 11:00:00 CEST | Press release
Nokia Corporation Managers’ transactions 24 April 2024 at 12:00 EEST Nokia Corporation - Managers' transactions (Martikainen) Transaction notification under Article 19 of EU Market Abuse Regulation. ____________________________________________ Person subject to the notification requirement Name: Martikainen, Piia Susanna Position: Closely associated person (1):Person Discharging Managerial Responsibilities In Issuer Name: Uitto, Tommi Position: Other senior manager Issuer: Nokia Corporation LEI: 549300A0JPRWG1KI7U06 Notification type: INITIAL NOTIFICATION Reference number: 59446/5/4 ____________________________________________ Transaction date: 2024-04-23 Venue: NASDAQ HELSINKI LTD (XHEL) Instrument type: SHARE ISIN: FI0009000681 Nature of the transaction: ACQUISITION Transaction details (1): Volume: 173 Unit price: 3.45110 EUR Aggregated transactions (1): Volume: 173 Volume weighted average price: 3.45110 EUR About Nokia At Nokia, we create technology that helps the world act together
ROCKWOOL A/S – transaktioner i henhold til aktietilbagekøbsprogram24.4.2024 10:52:51 CEST | pressemeddelelse
Selskabsmeddelelse for ROCKWOOL A/S Meddelelse nr. 19 – 2024 til Nasdaq Copenhagen 24. april 2024 ROCKWOOL A/S – transaktioner i henhold til aktietilbagekøbsprogram Som meddelt i selskabsmeddelelse nr. 02/2024 har ROCKWOOL A/S iværksat et aktietilbagekøbsprogram, som løber i perioden fra og med 8. februar 2024 og til og med den 7. februar 2025. I denne periode vil Selskabet købe egne aktier for op til maksimalt 160 mio. euro. Tilbagekøbsprogrammet gennemføres i henhold til EU-Kommissionens forordning nr. 596/2014 af 16. april 2014 og EU-Kommissionens delegerede forordning nr. 2016/1052 af 8. marts 2016, der tilsammen udgør ”Safe harbour” reguleringen. I perioden 17. – 23. april 2024 er foretaget følgende køb: DatoAntal B-aktierGennemsnitlig købspris B-aktier (DKK)Samlet beløb B-aktier (DKK)[I alt, seneste meddelelse]132.300291.065.94817. april 20244.0002.216,918.867.64018. april 20243.0002.205,996.617.97019. april 20244.0002.194,808.779.20022. april 20243.0002.246,256.738.75023. april
ROCKWOOL A/S – transactions in connection with share buy-back programme24.4.2024 10:52:51 CEST | Press release
Company announcement for ROCKWOOL A/S Release no. 19 – 2024 to Nasdaq Copenhagen 24 April 2024 ROCKWOOL A/S – transactions in connection with share buy-back programme As mentioned in announcement no. 02/2024, ROCKWOOL A/S has initiated a share buy-back programme which will run from 8 February 2024 until 7 February 2025. During this period, the Company will buy own shares for up to a maximum of 160 MEUR. The programme is implemented in accordance with EU Commission Regulation No 596/2014 of 16 April 2014 and EU Commission Delegated Regulation No 2016/1052 of 8 March 2016, which together constitute the “Safe Harbour” regulation. The following transactions have been executed during the period 17 – 23 April 2024: DateNumber of B sharesAverage purchase price B shares (DKK)Aggregate amount, B shares (DKK)[Accumulated, last announcement]132,300291,065,94817 April 20244,0002,216.918,867,64018 April 20243,0002,205.996,617,97019 April 20244,0002,194.808,779,20022 April 20243,0002,246.256,738,750
Festi hf.: Presentation of Q1 2024 results24.4.2024 10:37:21 CEST | Press release
Festi hf. published its Q1 2024 results after market closing on 23 April 2024. Please find attached the Q1 2024 investor presentation for investor meeting held today, Wednesday 24 April 2024 at 8:30. Attachment Festi hf. - Presentation of Q1 2024 results